LLY

934.48

-5.5%↓

JNJ

240.19

-0.84%↓

ABBV

221.83

-0.07%↓

NVS

154.93

+0.32%↑

AZN

191.77

+0.14%↑

LLY

934.48

-5.5%↓

JNJ

240.19

-0.84%↓

ABBV

221.83

-0.07%↓

NVS

154.93

+0.32%↑

AZN

191.77

+0.14%↑

LLY

934.48

-5.5%↓

JNJ

240.19

-0.84%↓

ABBV

221.83

-0.07%↓

NVS

154.93

+0.32%↑

AZN

191.77

+0.14%↑

LLY

934.48

-5.5%↓

JNJ

240.19

-0.84%↓

ABBV

221.83

-0.07%↓

NVS

154.93

+0.32%↑

AZN

191.77

+0.14%↑

LLY

934.48

-5.5%↓

JNJ

240.19

-0.84%↓

ABBV

221.83

-0.07%↓

NVS

154.93

+0.32%↑

AZN

191.77

+0.14%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

1.15 -0.86

Buy Sell

Overview

Share price change

24h

Current

Min

1.1400000000000001

Max

1.18

Key metrics
By Trading Economics
Income	-124K -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-2,364.792
Employees	161
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+93.97% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-20M 155M
Previous open	2.01
Previous close	1.15

News Sentiment

By Acuity

50%

150 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 mar 2026, 21:37 UTC

Acquisitions, Mergers, Takeovers

Lensar and Alcon Agree to Terminate Merger

16 mar 2026, 19:06 UTC

Major News Events

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

16 mar 2026, 17:44 UTC

Acquisitions, Mergers, Takeovers

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

16 mar 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 mar 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Oil Prices Decline -- Market Talk

16 mar 2026, 23:37 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

16 mar 2026, 23:05 UTC

Market Talk

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

16 mar 2026, 21:56 UTC

Market Talk

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

16 mar 2026, 21:41 UTC

Market Talk

Major News Events

Global Equities Roundup: Market Talk

16 mar 2026, 21:41 UTC

Market Talk

Major News Events

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

16 mar 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

16 mar 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

16 mar 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

16 mar 2026, 20:57 UTC

Acquisitions, Mergers, Takeovers

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

16 mar 2026, 20:51 UTC

Acquisitions, Mergers, Takeovers

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

16 mar 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 mar 2026, 20:50 UTC

Market Talk

Major News Events

Energy & Utilities Roundup: Market Talk

16 mar 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

16 mar 2026, 19:53 UTC

Major News Events

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

16 mar 2026, 19:43 UTC

Market Talk

Global Equities Roundup: Market Talk

16 mar 2026, 19:43 UTC

Market Talk

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

16 mar 2026, 19:37 UTC

Market Talk

Major News Events

Natural Gas Follows Oil Prices Lower -- Market Talk

16 mar 2026, 19:20 UTC

Major News Events

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

16 mar 2026, 19:17 UTC

Market Talk

Major News Events

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

16 mar 2026, 19:00 UTC

Market Talk

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

16 mar 2026, 18:23 UTC

Market Talk

LME Restarts Trading After Outage -- Market Talk

16 mar 2026, 17:36 UTC

Major News Events

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

16 mar 2026, 17:19 UTC

Market Talk

Grains Sink as Investors Steer Toward Equities -- Market Talk

16 mar 2026, 17:14 UTC

Major News Events

Trump Ends News Conference

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

93.97% upside

12 Months Forecast

Average 2.25 USD 93.97%

High 2.5 USD

Low 2 USD

Based on 4 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

150 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.